AI Summary
✦ ClarthaPrice Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 31 analysts
Fundamentals
Fundamentals institutional score is 86 using EVA spread proxy 9.5%; growth durability 73.4.
Valuation
Valuation institutional score is 33 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 59 using mean target upside 7.7%; dispersion penalty 19.3; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 61 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 5 recent ticker-linked news items.
Signal Summary
Market intelligence remains Neutral. fundamentals provide support, while valuation and market sentiment remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 26.4% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +1.98). Confidence: 86%.
Live forward EPS implies next-12-month EPS of ₹214.33. Applying the stock's normalized valuation corridor produces a fair range of ₹9,842.03 to ₹11,837.45, with base value near ₹11,022.99 (+26.0% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹214.33
Forward P/E
40.8x
Base Fair Value
₹11,022.99
Fair Range
₹9,842.03 - ₹11,837.45
Upside To Base
+26.0%
Estimate Source
Live forward EPS
Growth Estimate
+35.6%
5Y Average
44.18
Current
65.03
Overvalued
55.23
Undervalued
45.92
5Y Average
26.53
Current
39.04
Overvalued
31.53
Undervalued
19.97
5Y Average
3.39
Current
4.99
Overvalued
3.90
Undervalued
2.88
Peers & Comparison
Sector: Health Care · Theme: Hospitals & Diagnostic Centres
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
DR. REDDY S LABORATORIES DRREDDYPharmaceuticals | -5.6% | 10.0% | 30.7x Fair | -1% vs avg | -5.0% |
GRASIM INDUSTRIES LTD GRASIMCement | +10.5% | 2.8% | 45.5x Premium | +46% vs avg | +23.4% |
HINDALCO INDUSTRIES LTD HINDALCOMetals - Aluminium | +32.1% | 5.5% | 14.3x Undervalued | -54% vs avg | +58.0% |
BSE LIMITED BSEStock Exchanges & Ratings | +64.0% | 48.9% | 50.4x Premium | +62% vs avg | +50.1% |
HERO MOTOCORP LIMITED HEROMOTOCOTwo Wheelers | +34.9% | 10.7% | 21.1x Undervalued | -32% vs avg | +26.2% |
EICHER MOTORS LTD EICHERMOTTrucks & Buses | +31.5% | 23.2% | 38.1x Premium | +23% vs avg | +41.7% |
BAJAJ AUTO LIMITED BAJAJ-AUTOTwo Wheelers | +64.0% | 16.3% | 27.8x Fair | -11% vs avg | +42.5% |
HCL TECHNOLOGIES LTD HCLTECHIT Services & Consulting | +3.0% | 13.0% | 21.2x Undervalued | -32% vs avg | -8.8% |
APOLLO HOSPITALS ENTER. L trades at a premium (65.1x vs peer avg 31.1x), implying higher growth or quality expectations from the Hospitals & Diagnostic Centres cohort. Peers include DR. REDDY S LABORATORIES, GRASIM INDUSTRIES LTD, HINDALCO INDUSTRIES LTD — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹2.44K CrMar 2026Latest net profit
₹382 CrMar 2026Latest EPS
₹26.60Mar 2026Net margin
24.0%Mar 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Mar 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,641 | 1,688 | 1,866 | 1,824 | 1,895 | 1,937 | 2,135 | 2,055 | 2,075 | 2,168 | 2,356 | 2,364 | 2,438 |
| Expenses + | 1,218 | 1,271 | 1,387 | 1,374 | 1,444 | 1,466 | 1,595 | 1,543 | 1,554 | 1,622 | 1,763 | 1,770 | 1,843 |
| Operating Profit | 423 | 418 | 479 | 450 | 450 | 471 | 540 | 512 | 521 | 546 | 593 | 594 | 596 |
| OPM % | 26% | 25% | 26% | 25% | 24% | 24% | 25% | 25% | 25% | 25% | 25% | 25% | 24% |
| Other Income + | 43 | 18 | 65 | 52 | 46 | 27 | 121 | 108 | 92 | 32 | 141 | 97 | 90 |
| Interest | 61 | 61 | 60 | 61 | 69 | 64 | 65 | 62 | 63 | 59 | 58 | 62 | 63 |
| Depreciation | 97 | 93 | 93 | 97 | 115 | 103 | 108 | 108 | 130 | 123 | 122 | 127 | 128 |
| Profit before tax | 309 | 282 | 391 | 344 | 312 | 332 | 488 | 449 | 420 | 397 | 554 | 502 | 494 |
| Tax % | 26% | 24% | 25% | 24% | 24% | 24% | 24% | 24% | 21% | 23% | 24% | 24% | 23% |
| Net Profit + | 227 | 214 | 295 | 263 | 239 | 252 | 370 | 342 | 333 | 307 | 420 | 384 | 382 |
| EPS in Rs | 15.78 | 14.89 | 20.50 | 18.28 | 16.61 | 17.51 | 25.71 | 23.76 | 23.19 | 21.34 | 29.20 | 26.67 | 26.60 |
| Raw PDF | |||||||||||||
| YOY Sales Growth % | 15.49% | 10.37% | 8.80% | 11.33% | 15.47% | 14.70% | 14.41% | 12.63% | 9.54% | 11.94% | 10.34% | 15.03% | 17.50% |
| Material Cost % | 26.69% | 27.35% | 27.55% | 27.22% | 27.79% | 27.69% | 27.20% | 27.71% | 27.08% | 27.20% | 25.94% | 25.88% | 24.86% |
| Employee Cost % | 20.98% | 19.75% | 19.17% | 19.19% | 20.26% | 19.66% | 19.31% | 19.15% | 19.77% | 18.62% | 18.30% | 17.35% | 18.09% |
| Exceptional items | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -11 | 0 |
| Other income normal | 43 | 18 | 65 | 52 | 46 | 27 | 121 | 108 | 92 | 32 | 141 | 108 | 90 |
| Exceptional items AT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -9 | 0 |
| Profit excl Excep | 227 | 214 | 295 | 263 | 239 | 252 | 370 | 342 | 333 | 307 | 420 | 392 | 382 |
| Profit for PE | 227 | 214 | 295 | 263 | 239 | 252 | 370 | 342 | 333 | 307 | 420 | 392 | 382 |
| Profit for EPS | 227 | 214 | 295 | 263 | 239 | 252 | 370 | 342 | 333 | 307 | 420 | 384 | 382 |
| YOY Profit Growth % | 53% | -36% | 6% | 7% | 5% | 18% | 25% | 30% | 40% | 22% | 14% | 15% | 15% |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Notice Published In News Papers - 45Th AGM And Evoting Related Information; Record Date For Payment Of Dividend Etc
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation